Novo Nordisk a S: Form 20-F for the period ended Dec 31, 2023
Filed with the SEC on Jan 31, 2024 and accepted by EDGAR at Jan 31, 2024, 06:51 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2023-01-01 to 2023-12-31 | DKK 232.26bn | ifrs-full:Revenue |
| Cost of revenue | 12 months2023-01-01 to 2023-12-31 | DKK 35.77bn | ifrs-full:CostOfSales |
| Gross profit | 12 months2023-01-01 to 2023-12-31 | DKK 196.50bn | ifrs-full:GrossProfit |
| Operating income | 12 months2023-01-01 to 2023-12-31 | DKK 102.57bn | ifrs-full:ProfitLossFromOperatingActivities |
| Income tax | 12 months2023-01-01 to 2023-12-31 | DKK 20.99bn | ifrs-full:IncomeTaxExpenseContinuingOperations |
| Net income | 12 months2023-01-01 to 2023-12-31 | DKK 83.68bn | ifrs-full:ProfitLoss |
| Diluted EPS | 12 months2023-01-01 to 2023-12-31 | DKK 18.62 | ifrs-full:DilutedEarningsLossPerShare |
| Basic EPS | 12 months2023-01-01 to 2023-12-31 | DKK 18.67 | ifrs-full:BasicEarningsLossPerShare |
| Operating cash flow | 12 months2023-01-01 to 2023-12-31 | DKK 108.91bn | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months2023-01-01 to 2023-12-31 | DKK 25.81bn | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | At period end2023-12-31 | DKK 14.39bn | ifrs-full:CashAndCashEquivalents |
| Current assets | At period end2023-12-31 | DKK 139.65bn | ifrs-full:CurrentAssets |
| Total assets | At period end2023-12-31 | DKK 314.49bn | ifrs-full:Assets |
| Current liabilities | At period end2023-12-31 | DKK 169.66bn | ifrs-full:CurrentLiabilities |
| Total liabilities | At period end2023-12-31 | DKK 207.93bn | ifrs-full:Liabilities |
| Shareholders' equity | At period end2023-12-31 | DKK 106.56bn | ifrs-full:Equity |
Source: SEC EDGAR, the filing index for accession 0001628280-24-002635. Last ingested by Listed: Nov 4, 2026, 07:48 ET. Listed shows no prices and gives no investment advice.